Mitiglinide

Mitiglinide
Clinical data
Trade names Glufast
AHFS/Drugs.com International Drug Names
Routes of
administration
By mouth (tablets)
ATC code A10BX08 (WHO)
Identifiers
CAS Number 145375-43-5 N
PubChem (CID) 121891
DrugBank DB01252 YesY
ChemSpider 108739 YesY
UNII D86I0XLB13 YesY
KEGG D01854 YesY
ChEMBL CHEMBL471498 YesY
Chemical and physical data
Formula C19H25NO3
Molar mass 315.41 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Dosage

Mitiglinide is delivered in tablet form.

References

This article is issued from Wikipedia - version of the 11/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.